#abs0380 #acr22 @rheumnow OM1 PsA cohort retro: PsA pts w/comorbidities &prior biologic use (both TNFi&SEC) respond well to IXE after 12 mo even w/monotherapy:IXE mono (82% pts) change in CDAI from BL to 6 mo -3.6 points& 12 mo -4.9 pts (statistically significant for both) https://t.co/5dRk86A9Xr